Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 2,011 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| IN8bio Inc | INAB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.06 | -5.66% | 1.00 | 07:30:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.06 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 6 | 2,011 | - | 0.65 - 3.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:30:55 | formt | 1,851 | $ 1.00 | USD |
IN8bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 45.88M | 43.29M | - | 0 | -30.01M | -0.69 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
IN8bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INAB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.99 | 1.09 | 0.94 | 1.03 | 212,823 | 0.01 | 1.01% |
| 1 Month | 1.20 | 1.27 | 0.9164 | 1.09 | 702,197 | -0.20 | -16.67% |
| 3 Months | 1.30 | 1.45 | 0.9164 | 1.12 | 351,953 | -0.30 | -23.08% |
| 6 Months | 0.9526 | 2.48 | 0.65 | 1.39 | 486,652 | 0.0474 | 4.98% |
| 1 Year | 2.74 | 3.48 | 0.65 | 1.70 | 559,980 | -1.74 | -63.50% |
| 3 Years | 10.00 | 10.319 | 0.65 | 2.54 | 598,639 | -9.00 | -90.00% |
| 5 Years | 10.00 | 10.319 | 0.65 | 2.54 | 598,639 | -9.00 | -90.00% |
IN8bio Description
| IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. |
